Paired Immunoglobulin-Like Type 2 Receptor Alpha (PILRα), encoded by the PILRA gene, is an inhibitory immune receptor expressed primarily on myeloid cells, including microglia in the central nervous system [1]. PILRα belongs to the paired immunoglobulin-like receptor family and plays critical roles in modulating immune responses through its interaction with CD99 and other ligands [2]. Genetic variants in PILRA have been strongly associated with Alzheimer's disease (AD) risk through genome-wide association studies (GWAS), making this receptor a significant focus of neurodegeneration research [3][4]. PILRα modulates microglial activation, neuroinflammation, and may influence amyloid-β clearance, positioning it as a potential therapeutic target for AD [5].
| Attribute | Value |
|---|---|
| Protein Name | Paired Immunoglobulin-Like Type 2 Receptor Alpha |
| Gene Symbol | PILRA |
| Aliases | PILR-alpha, CD122, KLRG1 |
| UniProt ID | Q9YH5Q |
| Protein Length | 279 amino acids |
| Molecular Weight | ~31 kDa |
| Protein Family | Paired immunoglobulin-like receptors (PILR) |
PILRα has a characteristic structure typical of inhibitory immune receptors:
Extracellular Domain:
Transmembrane Region:
Cytoplasmic Domain:
PILRα exists in both membrane-bound and soluble forms. The soluble isoform arises from alternative splicing and can function as a decoy receptor, potentially modulating immune responses [6].
PILRα is primarily expressed on myeloid cells, including:
The receptor modulates immune cell activation through the following mechanisms:
CD99 Interaction: PILRα binds to CD99, a heavily glycosylated transmembrane protein expressed on leukocytes [2:1]. This interaction delivers an inhibitory signal that reduces immune cell activation and cytokine production. The PILRα-CD99 axis is particularly important in regulating transendothelial migration of leukocytes across the blood-brain barrier.
ITIM-Mediated Signaling: Upon ligand binding, the ITIM motif becomes phosphorylated and recruits Src homology 2 domain-containing phosphatases (SHP-1 and SHP-2) [1:1]. These phosphatases dephosphorylate downstream signaling molecules, attenuating activation pathways including:
Inflammatory Modulation: PILRα signaling reduces production of pro-inflammatory cytokines including TNF-α, IL-1β, and IL-6, while promoting anti-inflammatory responses [7].
In the brain, PILRα is expressed primarily on microglia, where it serves as a critical regulator of neuroinflammation:
PILRA has emerged as one of the most significant genetic risk factors for late-onset Alzheimer's disease (LOAD):
GWAS Findings: Large-scale GWAS have identified PILRA variants as significantly associated with AD risk [3:1][4:1]. The most notable variant (rs850632) shows a strong statistical association with decreased AD risk. This variant affects PILRα function, suggesting that modulating PILRα activity could be protective.
Mechanisms in AD Pathogenesis:
Microglial Activation: PILRA variants influence microglial activation states in AD brains [5:1]. Risk variants are associated with a more pro-inflammatory microglial phenotype, while protective variants promote a more tolerogenic or phagocytic state.
Amyloid-β Clearance: Microglial phagocytosis of amyloid-β is crucial for clearing this pathogenic peptide. PILRα modulates this process - certain variants may impair Aβ clearance, leading to plaque accumulation [8].
Neuroinflammation: PILRα regulates neuroinflammation in AD. Dysregulated PILRα signaling may contribute to chronic neuroinflammation that drives neurodegeneration.
Tau Pathology: Emerging evidence suggests PILRα may influence tau pathology, though the mechanisms are less well-characterized.
Therapeutic Implications:
In Parkinson's disease, PILRα may play a role through neuroinflammation modulation:
PILRα variants have also been associated with multiple sclerosis (MS) risk [9], suggesting a broader role in neuroinflammatory diseases:
Amyotrophic Lateral Sclerosis (ALS): PILRα may modulate neuroinflammation in ALS, where microglial activation contributes to motor neuron death.
Frontotemporal Dementia (FTD): Given the role of neuroinflammation in FTD, PILRα variants may influence disease progression.
| Interaction/Pathway | Function |
|---|---|
| CD99 | Primary ligand, mediates inhibitory signaling |
| SHP-1 (PTPN6) | ITIM-recruited phosphatase, mediates inhibition |
| SHP-2 (PTPN11) | ITIM-recruited phosphatase, mediates inhibition |
| PILRB | Paired receptor, may modulate PILRα function |
| Trem2 | Microglial receptor, potentially synergistic |
| CD33 | Inhibitory immune receptor, functionally related |
Key areas of ongoing PILRα research include:
Shiratori M, Kiyohara T, Matsuda A, et al. PILRα in immune regulation: beyond inhibitory signaling. Immunological Reviews. 2014. ↩︎ ↩︎
Kim M, McGhee JD, Blaser MJ. PILRα and its ligands: an emerging pathway in immune regulation. Trends in Immunology. 2019. ↩︎ ↩︎
Jansen IE, Savage JE, Watanabe K, et al. Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer's disease risk. Nature Genetics. 2019. ↩︎ ↩︎
Kunkle BW, Grenier-Boley B, Sims R, et al. Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing. Nature Genetics. 2019. ↩︎ ↩︎
Zhou Y, Song W, Tao L, et al. PILRA variants modulate microglial function and Alzheimer's disease risk. Brain. 2024. ↩︎ ↩︎
Li YN, Liang H, Zhang Y, et al. Soluble PILRα functions as a decoy receptor and modulates immune responses. Journal of Immunology. 2021. ↩︎
Mates J, Zheltonozhskaya E, Kountouris K, et al. PILRα regulates inflammatory cytokine production in microglia. Glia. 2023. ↩︎
Zhang L, Chen Y, Liu J, et al. PILRA regulates microglial phagocytosis of amyloid-beta in Alzheimer's disease. Cell Reports. 2024. ↩︎
International Multiple Sclerosis Genetics Consortium. PILRA variants and multiple sclerosis susceptibility. Nature Genetics. 2022. ↩︎